Verrica Pharmaceuticals Inc. Operating Expenses
Verrica Pharmaceuticals Inc. (VRCA) reported Operating Expenses of $18.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. operating expenses for the quarter ending 2026-06-30 was $18.96M, a 69.40% increase year-over-year.
- Verrica Pharmaceuticals Inc. operating expenses for the quarter ending 2026-03-31 was $14.74M, a 27.39% increase year-over-year.
- Verrica Pharmaceuticals Inc. operating expenses for the quarter ending 2025-12-31 was $12.28M, a 4.51% increase year-over-year.
- Verrica Pharmaceuticals Inc. operating expenses for the quarter ending 2025-09-30 was $12.72M, a 32.80% decline year-over-year.
- Verrica Pharmaceuticals Inc. operating expenses for fiscal 2025 was $47.76M, a 35.00% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. operating expenses for fiscal 2024 was $73.48M, a 3.67% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. operating expenses for fiscal 2023 was $70.88M, a 133.72% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. operating expenses for fiscal 2022 was $30.33M, a 29.32% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.96M 10-Q · filed 2026-08-06 | $33.70M 10-Q · filed 2026-08-06 | $45.98M derived: sum of 3 quarters · filed 2026-08-06 | $58.70M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $14.74M 10-Q · filed 2026-05-12 | $27.02M derived: sum of 2 quarters · filed 2026-05-12 | $39.74M derived: sum of 3 quarters · filed 2026-05-12 | $50.93M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $12.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $25.00M derived: sum of 2 quarters · filed 2026-03-11 | $36.19M derived: sum of 3 quarters · filed 2026-08-06 | $47.76M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $12.72M 10-Q · filed 2025-11-14 | $23.91M derived: sum of 2 quarters · filed 2026-08-06 | $35.48M 10-Q · filed 2025-11-14 | $47.23M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $11.19M 10-Q · filed 2026-08-06 | $22.76M 10-Q · filed 2026-08-06 | $34.52M derived: sum of 3 quarters · filed 2026-08-06 | $53.44M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $11.57M 10-Q · filed 2026-05-12 | $23.32M derived: sum of 2 quarters · filed 2026-05-12 | $42.25M derived: sum of 3 quarters · filed 2026-05-12 | $62.63M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $11.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $30.68M derived: sum of 2 quarters · filed 2026-03-11 | $51.06M derived: sum of 3 quarters · filed 2026-03-11 | $73.48M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $18.92M 10-Q · filed 2025-11-14 | $39.31M derived: sum of 2 quarters · filed 2025-11-14 | $61.73M 10-Q · filed 2025-11-14 | $86.86M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $20.38M 10-Q · filed 2025-08-12 | $42.81M 10-Q · filed 2025-08-12 | $67.93M derived: sum of 3 quarters · filed 2025-08-12 | $94.77M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $22.43M 10-Q · filed 2025-05-13 | $47.55M derived: sum of 2 quarters · filed 2025-05-13 | $74.38M derived: sum of 3 quarters · filed 2025-05-13 | $86.18M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $25.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $51.96M derived: sum of 2 quarters · filed 2025-03-11 | $63.76M derived: sum of 3 quarters · filed 2025-03-11 | $70.88M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $26.83M 10-Q · filed 2024-11-05 | $38.63M derived: sum of 2 quarters · filed 2024-11-05 | $45.76M 10-Q · filed 2024-11-05 | $52.04M derived: sum of 4 quarters · filed 2024-11-05 | |||
| 2023-06-30 | $11.80M 10-Q · filed 2024-08-14 | $18.92M 10-Q · filed 2024-08-14 | $25.20M derived: sum of 3 quarters · filed 2024-08-14 | $32.07M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $7.13M 10-Q · filed 2024-05-13 | $13.40M derived: sum of 2 quarters · filed 2024-05-13 | $20.28M derived: sum of 3 quarters · filed 2024-05-13 | $29.61M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $13.15M derived: sum of 2 quarters · filed 2024-02-29 | $22.48M derived: sum of 3 quarters · filed 2024-02-29 | $30.33M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $6.87M 10-Q · filed 2023-11-09 | $16.21M derived: sum of 2 quarters · filed 2023-11-09 | $24.05M 10-Q · filed 2023-11-09 | $32.52M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $9.34M 10-Q · filed 2023-08-08 | $17.18M 10-Q · filed 2023-08-08 | $25.65M derived: sum of 3 quarters · filed 2023-08-08 | $37.41M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | $7.84M 10-Q · filed 2023-05-09 | $16.31M derived: sum of 2 quarters · filed 2023-05-09 | $28.08M derived: sum of 3 quarters · filed 2023-05-09 | $38.81M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $20.24M derived: sum of 2 quarters · filed 2023-03-06 | $30.97M derived: sum of 3 quarters · filed 2023-03-06 | $42.91M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $11.77M 10-Q · filed 2022-11-07 | $22.50M derived: sum of 2 quarters · filed 2022-11-07 | $34.44M 10-Q · filed 2022-11-07 | $46.47M derived: sum of 4 quarters · filed 2022-11-07 | |||
| 2021-06-30 | $10.73M 10-Q · filed 2022-08-11 | $22.67M 10-Q · filed 2022-08-11 | $34.70M derived: sum of 3 quarters · filed 2022-08-11 | $44.34M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $11.94M 10-Q · filed 2022-05-09 | $23.97M derived: sum of 2 quarters · filed 2022-05-09 | $33.61M derived: sum of 3 quarters · filed 2022-05-09 | $42.24M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $12.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $21.67M derived: sum of 2 quarters · filed 2022-03-02 | $30.30M derived: sum of 3 quarters · filed 2022-03-02 | $40.18M 10-K · filed 2022-03-02 | |||
| 2020-09-30 | $9.64M 10-Q · filed 2021-11-12 | $18.27M derived: sum of 2 quarters · filed 2021-11-12 | $28.15M 10-Q · filed 2021-11-12 | $36.14M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $8.63M 10-Q · filed 2021-08-10 | $18.51M 10-Q · filed 2021-08-10 | $26.50M derived: sum of 3 quarters · filed 2021-08-10 | $33.04M derived: sum of 4 quarters · filed 2021-08-10 | |||
| 2020-03-31 | $9.88M 10-Q · filed 2021-05-07 | $17.87M derived: sum of 2 quarters · filed 2021-05-07 | $24.41M derived: sum of 3 quarters · filed 2021-05-07 | $31.93M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $7.99M 10-K · filed 2020-03-13 | $14.53M derived: sum of 2 quarters · filed 2020-11-09 | $22.05M derived: sum of 3 quarters · filed 2020-11-09 | $30.08M 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $6.54M 10-Q · filed 2020-11-09 | $14.06M derived: sum of 2 quarters · filed 2020-11-09 | $22.09M 10-Q · filed 2020-11-09 | $30.28M derived: sum of 4 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $7.52M 10-Q · filed 2020-08-05 | $15.55M 10-Q · filed 2020-08-05 | $23.73M derived: sum of 3 quarters · filed 2020-08-05 | $30.07M derived: sum of 4 quarters · filed 2020-08-05 | |||
| 2019-03-31 | $8.03M 10-Q · filed 2020-05-07 | $16.21M derived: sum of 2 quarters · filed 2020-05-07 | $22.55M derived: sum of 3 quarters · filed 2020-05-07 | $28.02M derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $8.19M 10-K · filed 2020-03-13 | $14.52M derived: sum of 2 quarters · filed 2020-03-13 | $19.99M derived: sum of 3 quarters · filed 2020-03-13 | $21.88M 10-K · filed 2020-03-13 | |||
| 2018-09-30 | $6.33M 10-K · filed 2020-03-13 | $7.17M 10-Q · filed 2018-11-07 | $11.80M derived: sum of 2 quarters · filed 2020-03-13 | $13.69M 10-Q · filed 2019-11-06 | $15.19M 10-Q · filed 2018-11-07 | $15.12M derived: sum of 4 quarters · filed 2020-03-13 | |
| 2018-06-30 | $5.47M 10-K · filed 2020-03-13 | $6.11M 10-Q · filed 2018-08-07 | $7.36M 10-Q · filed 2019-08-07 | $8.03M 10-Q · filed 2018-08-07 | $8.79M derived: sum of 3 quarters · filed 2020-03-13 | $10.15M derived: sum of 4 quarters · filed 2020-03-13 | |
| 2018-03-31 | $1.89M 10-K · filed 2020-03-13 | $3.32M derived: sum of 2 quarters · filed 2020-03-13 | $4.68M derived: sum of 3 quarters · filed 2020-03-13 | $5.78M derived: sum of 4 quarters · filed 2020-03-13 | |||
| 2017-12-31 | $1.43M 10-K · filed 2019-03-07 | $2.79M derived: sum of 2 quarters · filed 2019-03-07 | $3.89M derived: sum of 3 quarters · filed 2019-03-07 | $4.46M 10-K · filed 2019-03-07 | |||
| 2017-09-30 | $1.36M 10-K · filed 2019-03-07 | $2.45M derived: sum of 2 quarters · filed 2019-03-07 | $3.02M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | $1.09M 10-K · filed 2019-03-07 | $1.67M 10-Q · filed 2018-08-07 | |||||
| 2017-03-31 | $570.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |